Abstract: 【Abstract】Chronic kidney disease-mineral and bone disorder (CKD-MBD) is one of the major complications and one of the major death causes in CKD patients. Currently, the treatment of CKD-MBD mainly includes phosphorus binding agent, active vitamin D and its analogues, calcimimetics and parathyroidectomy. Active vitamin D and its analogues are widely used clinically, which can reduce parathyroid hormone level and alleviate bone damage of osteoporosis and high transport bone disease. However, inappropriate use of these medications may cause hypercalcemia, hyperphosphatemia and aggravation of vascular calcification. This article introduces recent progresses in the treatment of CKD-MBD using active vitamin D and its analogues as well as the renewal of KDIGO guide 2017 for CKD-MBD.

Key words: Active vitamin D, Calcitriol, Paricalcitol, Chronic kidney disease-mineral and bone disorder